Myriad Pushing Ahead With Payors on GeneSight as Data From Large Randomized Study is Published

Jan 07, 2019

|

NEW YORK (GenomeWeb) – Myriad Genetics is hoping that data from a large randomized controlled study published last week on GeneSight will change the reimbursement prospects for the pharmacogenetic test, as well as shift the standard of care for treating depression.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

For Scientific Talent

Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.

Agency Pick Worries Brazilian Researchers

ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.

Speedy Work

The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.

PLOS Papers Include Greenlander BMI GWAS, Metabolic MicroRNA Marker Search, More

In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.

Menu

Myriad Pushing Ahead With Payors on GeneSight as Data From Large Randomized Study is Published

To read the full story....

Breaking News

PerkinElmer Q4 Revenues Rise 7 Percent

CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients

Meridian Stock Rises 21 Percent After Reagent Mix Used in Coronavirus Testing

UK Newborn Trial to Assess PCR Test for Antibiotic-Induced Hearing Loss

Whole-Genome Sequencing, Deep Phenotyping Shows Many Adults Harbor Pathogenic Genetic Variants

QuantuMDx Raises $14M to Support Development of POC Genotyping Assay